

## Australia's TGA approves Next Science's Bactisure

**Sydney, Australia, Wednesday, 1 July 2020:** Next Science Limited (ASX:NXS) is pleased to announce that its Bactisure Surgical Lavage has been cleared by the Therapeutic Goods Administration (**TGA**) for sale in Australia.

The approval means that Bactisure will now be sold in Australia by Zimmer Biomet, a leading orthopaedic implant supplier, and Next Science's appointed global distributor for the product.

Bactisure is used to wash out the surgical cavity eliminating the biofilm and any microscopic bacteria, virus or fungus that can cause later infection. A clinical trial, across 7 sites in the United States on Infected Total Knee joint replacements found that there was a profound reduction in the recoverable bacteria after the application of the Bactisure, with only 10% of individuals bearing a new or continuing infection at the end of the 90 day observation period.<sup>1</sup>

Bactisure has been sold in the United States, through Zimmer Biomet, since 2017. It is also sold in Canada, New Zealand and South Africa. As announced on 3 March 2020, Bactisure has also received CE Mark approval allowing sales in Europe.

Managing Director Judith Mitchell said "We are thrilled that we can now offer our technology to Australian surgeons to help them manage their patients in eliminating surgical site infections".

Further information:

**Judith Mitchell**

Managing Director, Next Science Limited  
Phone: +61 2 9375 7989  
Email: [investorqueries@nextscience.com](mailto:investorqueries@nextscience.com)

**Michael Brown**

Pegasus Advisory  
Phone: +61 400 248 080  
Email: [mbrown@pegasusadvisory.com.au](mailto:mbrown@pegasusadvisory.com.au)

Approved and authorised for release by Next Science's Disclosure Committee.

### About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and commercialisation of its proprietary Xbio™ technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. Website: [www.nextscience.com](http://www.nextscience.com).

1. <https://www.zimmerbiomet.com/content/dam/zimmer-biomet/medical-professionals/surgical-and-cement/bactisure-wound-lavage/2656.1%20US-en%20Bactisure%20White%20Paper.pdf>